Episurf Medical’s implants approved for sale in Saudi Arabia
Episurf Medical (NASDAQ: EPIS B) today announces that the Saudi Food & Drug Authority (SFDA) has approved the company’s implant technologies Episealer® Knee and Episealer® Talus for the Saudi market. Included in the approval is also the ankle device Talus Osteotomy Guide. The approval follows a review process. “We are very happy that we are continuing to execute on our global strategy. Saudi Arabia is an exciting market. We have been looking at the Middle East region for several years, and I am pleased that we are now taking the next step in Saudi Arabia”, says Pål Ryfors, CEO Episurf